Opus Genetics, Inc.
OPGx-BEST1
BEST1-Related IRD
Resolved
7days ago
Phase 2 readout · Jun 30, 2026
What's at stake
Phase 2 trial results for OPGx-BEST1 in BEST1-Related IRD are due Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Initial data expected this quarter at Macula Society with 3-month results from the entire Cohort 1 expected in mid-2026.”